Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term anabolic therapy in the elderly.

M D Lye, A E Ritch

    Age and Ageing
    |November 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Stanozolol, an anabolic agent, did not improve weight or activity in the elderly over 12 months. However, it significantly increased hemoglobin and packed cell volume without androgenic side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Fluctuating confusional state due to massive macro-prolactinoma resulting in obstructive hydrocephalus.

    Age and ageing·2001
    Same author

    Management of urinary incontinence.

    Journal of clinical pharmacy and therapeutics·2000
    Same author

    Ethnic influence on health and dependency of elderly inner city residents.

    Journal of the Royal College of Physicians of London·1996
    Same author

    Senior registrar training in geriatric medicine 1977-1990.

    Journal of the Royal College of Physicians of London·1991
    Same author

    c-myc oncoprotein in bronchial carcinoma: expression in all major morphological types.

    Anticancer research·1990
    Same author

    Sick sinus syndrome aggravated by carbamazepine therapy for epilepsy.

    Postgraduate medical journal·1986

    Area of Science:

    • Gerontology
    • Pharmacology
    • Sports Medicine

    Background:

    • Anabolic agents like stanozolol are explored for potential benefits in the elderly.
    • Long-term effects of stanozolol in this population remain largely uncharacterized.

    Purpose of the Study:

    • To evaluate the long-term efficacy and safety of stanozolol in elderly individuals.
    • To assess the impact of stanozolol on body composition, activity levels, and hematological profiles.

    Main Methods:

    • A 12-month, double-blind, placebo-controlled trial was conducted.
    • Measurements included weight, body fat, fat-free mass, behavior, activity, and detailed biochemical/hematological profiles.
    • Participants received either stanozolol or a placebo.

    Related Experiment Videos

    Main Results:

    • No significant differences were observed in weight, fat, fat-free mass, or activity levels between the stanozolol and placebo groups.
    • The stanozolol group showed significant increases in hemoglobin at six and 12 months, and packed cell volume at 12 months.
    • No androgenic side effects were reported in the active treatment group.

    Conclusions:

    • Stanozolol did not demonstrate efficacy in improving body composition or activity levels in the elderly over a 12-month period.
    • The study identified significant hematological changes (hemoglobin, packed cell volume) with stanozolol use.
    • Stanozolol was well-tolerated, with no observed androgenic side effects during the trial.